Review



retrograde aav helper vector  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Addgene inc retrograde aav helper vector
    Retrograde Aav Helper Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 83 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pmc11411590-51-30-42?v=Addgene+inc
    Average 94 stars, based on 83 article reviews
    retrograde aav helper vector - by Bioz Stars, 2026-08
    94/100 stars

    Images



    Similar Products

    95
    PackGene Biotech lnc aav production
    Aav Production, supplied by PackGene Biotech lnc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pmc12907561-115-1-9?v=PackGene+Biotech+lnc
    Average 95 stars, based on 1 article reviews
    aav production - by Bioz Stars, 2026-08
    95/100 stars
      Buy from Supplier

    90
    Vector Biolabs vb4870 aav2 retro hsyn1 egfp 2a icre wpre vector biolabs cat
    Vb4870 Aav2 Retro Hsyn1 Egfp 2a Icre Wpre Vector Biolabs Cat, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pm36170832-207-91-93?v=Vector+Biolabs
    Average 90 stars, based on 1 article reviews
    vb4870 aav2 retro hsyn1 egfp 2a icre wpre vector biolabs cat - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    95
    PackGene Biotech lnc premade aav vector
    Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in <t>AAV</t> preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding <t>either</t> <t>ZFR11-VP1-mCherry</t> ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
    Premade Aav Vector, supplied by PackGene Biotech lnc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pmc12930510-148-5-10?v=PackGene+Biotech+lnc
    Average 95 stars, based on 1 article reviews
    premade aav vector - by Bioz Stars, 2026-08
    95/100 stars
      Buy from Supplier

    94
    Addgene inc retrograde aav helper vector
    Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in <t>AAV</t> preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding <t>either</t> <t>ZFR11-VP1-mCherry</t> ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
    Retrograde Aav Helper Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pmc11411590-51-30-42?v=Addgene+inc
    Average 94 stars, based on 1 article reviews
    retrograde aav helper vector - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    90
    Vigene Biosciences aav vectors raav2-retro-hsyn-cre
    Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in <t>AAV</t> preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding <t>either</t> <t>ZFR11-VP1-mCherry</t> ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
    Aav Vectors Raav2 Retro Hsyn Cre, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pm37734380-246-36-45?v=Vigene+Biosciences
    Average 90 stars, based on 1 article reviews
    aav vectors raav2-retro-hsyn-cre - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    96
    Addgene inc retro aav vector
    Figure 5. Expansion and imaging of a large volume of macaque brain. A 1 cm×1 cm×1.5 cm block of macaque primary motor cortex was expanded (3×) and imaged on the ExA-SPIM (Videos 7–9). Corticospinal neurons were transduced by <t>injecting</t> <t>tdTomato-expressing</t> <t>retro-AAV</t> into the spinal cord. (a–b) Maximum intensity projections of the imaged volume pseudo-colored by depth. The axes descriptors in (a) indicate the 5×3 tiling used to image this volume. (c–f) Fine axonal and dendritic structures including descending axons, collaterals, and dendritic spines are clearly discernible in the images throughout the entire volume. See Video 10. Images are displayed as maximum intensity projections with the following thicknesses: (a) 23 mm, (b) 45 mm, (c–f) 1 mm. Inset scale bars correspond to 10 µm post tissue expansion unless otherwise specified.
    Retro Aav Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/10__7554_slash_elife__91979-407-30-36?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    retro aav vector - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    96
    Addgene inc vectors aav retro pmsyn1 ebfp cre and paav 8 hsyn dio hm4d gi mcherry
    Figure 5. Expansion and imaging of a large volume of macaque brain. A 1 cm×1 cm×1.5 cm block of macaque primary motor cortex was expanded (3×) and imaged on the ExA-SPIM (Videos 7–9). Corticospinal neurons were transduced by <t>injecting</t> <t>tdTomato-expressing</t> <t>retro-AAV</t> into the spinal cord. (a–b) Maximum intensity projections of the imaged volume pseudo-colored by depth. The axes descriptors in (a) indicate the 5×3 tiling used to image this volume. (c–f) Fine axonal and dendritic structures including descending axons, collaterals, and dendritic spines are clearly discernible in the images throughout the entire volume. See Video 10. Images are displayed as maximum intensity projections with the following thicknesses: (a) 23 mm, (b) 45 mm, (c–f) 1 mm. Inset scale bars correspond to 10 µm post tissue expansion unless otherwise specified.
    Vectors Aav Retro Pmsyn1 Ebfp Cre And Paav 8 Hsyn Dio Hm4d Gi Mcherry, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/pmc09797209-57-7-25?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    vectors aav retro pmsyn1 ebfp cre and paav 8 hsyn dio hm4d gi mcherry - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    95
    Addgene inc vectors aav retro pmsyn1 ebfp cre and either paav 8 hsyn dio hm4d gi mcherry
    Figure 5. Expansion and imaging of a large volume of macaque brain. A 1 cm×1 cm×1.5 cm block of macaque primary motor cortex was expanded (3×) and imaged on the ExA-SPIM (Videos 7–9). Corticospinal neurons were transduced by <t>injecting</t> <t>tdTomato-expressing</t> <t>retro-AAV</t> into the spinal cord. (a–b) Maximum intensity projections of the imaged volume pseudo-colored by depth. The axes descriptors in (a) indicate the 5×3 tiling used to image this volume. (c–f) Fine axonal and dendritic structures including descending axons, collaterals, and dendritic spines are clearly discernible in the images throughout the entire volume. See Video 10. Images are displayed as maximum intensity projections with the following thicknesses: (a) 23 mm, (b) 45 mm, (c–f) 1 mm. Inset scale bars correspond to 10 µm post tissue expansion unless otherwise specified.
    Vectors Aav Retro Pmsyn1 Ebfp Cre And Either Paav 8 Hsyn Dio Hm4d Gi Mcherry, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/retro+aav+vector/bio_rxiv__2022__09__13__507801-60-7-26?v=Addgene+inc
    Average 95 stars, based on 1 article reviews
    vectors aav retro pmsyn1 ebfp cre and either paav 8 hsyn dio hm4d gi mcherry - by Bioz Stars, 2026-08
    95/100 stars
      Buy from Supplier

    Image Search Results


    Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

    Journal: ACS Synthetic Biology

    Article Title: Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control

    doi: 10.1021/acssynbio.5c00188

    Figure Lengend Snippet: Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

    Article Snippet: The mCherry construct was a premade AAV vector purchased from PackGene Biotech, (ssAAV-CAG-mCherry.WPRE.SV40pA, cat. no. AAV-EA022).

    Techniques: Control, Quantitative RT-PCR, Expressing, Immunohistochemical staining, Staining, Negative Control, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

    Figure 5. Expansion and imaging of a large volume of macaque brain. A 1 cm×1 cm×1.5 cm block of macaque primary motor cortex was expanded (3×) and imaged on the ExA-SPIM (Videos 7–9). Corticospinal neurons were transduced by injecting tdTomato-expressing retro-AAV into the spinal cord. (a–b) Maximum intensity projections of the imaged volume pseudo-colored by depth. The axes descriptors in (a) indicate the 5×3 tiling used to image this volume. (c–f) Fine axonal and dendritic structures including descending axons, collaterals, and dendritic spines are clearly discernible in the images throughout the entire volume. See Video 10. Images are displayed as maximum intensity projections with the following thicknesses: (a) 23 mm, (b) 45 mm, (c–f) 1 mm. Inset scale bars correspond to 10 µm post tissue expansion unless otherwise specified.

    Journal: eLife

    Article Title: Expansion-assisted selective plane illumination microscopy for nanoscale imaging of centimeter-scale tissues

    doi: 10.7554/elife.91979

    Figure Lengend Snippet: Figure 5. Expansion and imaging of a large volume of macaque brain. A 1 cm×1 cm×1.5 cm block of macaque primary motor cortex was expanded (3×) and imaged on the ExA-SPIM (Videos 7–9). Corticospinal neurons were transduced by injecting tdTomato-expressing retro-AAV into the spinal cord. (a–b) Maximum intensity projections of the imaged volume pseudo-colored by depth. The axes descriptors in (a) indicate the 5×3 tiling used to image this volume. (c–f) Fine axonal and dendritic structures including descending axons, collaterals, and dendritic spines are clearly discernible in the images throughout the entire volume. See Video 10. Images are displayed as maximum intensity projections with the following thicknesses: (a) 23 mm, (b) 45 mm, (c–f) 1 mm. Inset scale bars correspond to 10 µm post tissue expansion unless otherwise specified.

    Article Snippet: Spinal injection procedure and motor cortex collection To retrogradely label corticospinal neurons in the hand- wrist and trunk regions of primary motor cortex in a pigtail macaque, we injected a retro AAV vector (rAAV2- CAG- tdTomato; Addgene plasmid #59462 packaged in- house, titer of 1.88×1013) into the left lateral funiculus and ventrolateral part of the gray matter in the C6/C7 spinal segments.

    Techniques: Imaging, Blocking Assay, Expressing